MM-008 trial: Pharmacokinetics (PK) and tolerability of pomalidomide plus low-dose dexamethasone (POM plus LoDEX) in relapsed/refractory multiple myeloma (RRMM) patients with renal impairment (RI).
Jeffrey Matous
Consultant or Advisory Role - Celgene
Honoraria - Celgene
David Samuel DiCapua Siegel
Honoraria - Celgene; Merck; Millennium; Onyx
Hien Kim Duong
Honoraria - Celgene
Research Funding - Celgene
Claudia Kasserra
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Lars Sternas
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Christian Jacques
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Kenneth Klesczewski
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
Mohamed H. Zaki
Research Funding - Celgene
Jatin J. Shah
Consultant or Advisory Role - Array BioPharma; Celgene; Novartis; Onyx
Research Funding - Array BioPharma; Bristol-Myers Squibb; Celgene; Millennium; Novartis; Onyx